Connect with us

Technology

High Throughput Screening (HTS) Market to Grow by USD 19.9 Billion (2024-2028), Boosted by Rising R&D Investments, with AI Redefining Market Landscape – Technavio

Published

on

NEW YORK, Jan. 31, 2025 /PRNewswire/ — Report with market evolution powered by AI – The global high throughput screening (HTS) market size is estimated to grow by USD 19.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 12.12%  during the forecast period. Rise in R and D investments is driving market growth, with a trend towards increasing focus on promotional activities. However, shortage of trained healthcare professionals  poses a challenge. Key market players include Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

High Throughput Screening (HTS) Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 12.12%

Market growth 2024-2028

USD 19.9 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

11.64

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Japan, China, Germany, and France

Key companies profiled

Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc.

Market Driver

High-throughput screening (HTS) is a key trend in the life sciences sector, particularly in the areas of drug discovery and research for complex illnesses like cancer and neurological disorders. HTS allows for the rapid testing of large compound libraries using automated equipment such as robotic arms and microplate readers. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to analyze genomic data and chemical databases for target identification. Biotech startups and academic institutions are driving innovation in this field, with pharmaceutical corporations and research organizations collaborating to advance drug development. HTS is also used in stem cell research, toxicology, and open innovation models. HTS service providers offer instruments, software, and consumables to support this research. HTS is transforming the biopharmaceutical industry, enabling precision medicine and the repurposing of existing drugs for new indications. With advancements in technology, HTS is becoming more accessible to a wider range of organizations, including biotechnology startups and clinical trials. Despite these advancements, challenges remain, including false-positive findings and the need for specialized equipment maintenance. Overall, HTS is a vital tool in the global healthcare sector’s quest to develop new products and services for the detection and treatment of chronic diseases. 

The High Throughput Screening (HTS) market presents unique challenges for vendors due to its specialized nature and niche end-users. Brand and product visibility play a limited role in sales, and advertising and marketing are restricted. Key players in the industry recognize this issue and are promoting HTS through their websites and additional support materials. Thermo Fisher Scientific, for instance, provides explanatory documents, brochures, and interactive videos on YouTube to help end-users understand the technique better. Despite these efforts, there is a significant lack of awareness about HTS. Vendors must focus on improving their distribution networks to make these products readily available to end-users. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

High-throughput screening (HTS) is a crucial process in the biotechnology industry, enabling the rapid identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. The market for HTS is vast and diverse, with players including academic institutions, biotech startups, and pharmaceutical corporations. Challenges in this field include managing large data sets from compound libraries, dealing with false-positive findings, and maintaining specialized equipment. HTS involves the use of automation, robotics, and specialized instruments like microplate readers and high-resolution imaging systems. Data analytics is essential for making sense of the vast amounts of data generated. Machine learning and data management systems help in data organization, retrieval, integration, and storage. HTS is not just limited to pharmaceutical companies but also extends to the global healthcare sector, research organizations, and contract research organizations. Collaborative networks and HTS service providers play a significant role in driving innovation through open innovation models. HTS is also used in stem cell research, toxicology, and drug development. HTS involves various techniques like cell-based assays, lab-on-a-chip, and label-free technology. Biochemical screening and target identification are critical components of the HTS process. Drug repurposing initiatives, such as those from Relay Therapeutics, are gaining popularity in the biopharmaceutical industry due to their potential to bring new drugs to market faster and more cost-effectively. The HTS market is expected to grow significantly due to the increasing focus on precision medicine and the need for new drugs to address chronic diseases. Consumables, software, and services are essential products and services in the HTS market. The use of technology in HTS, such as automation and advanced detection techniques, is transforming the drug discovery process. Despite the challenges, the future of HTS looks promising, with advancements in technology and a growing focus on collaboration and open innovation models. The use of HTS in drug discovery and development is expected to revolutionize the way we approach complex illnesses and bring new treatments to market.In today’s fast-paced pharmaceutical and biotechnology industries, High Throughput Screening (HTS) has become a crucial tool for discovering new drugs and optimizing existing ones. However, the successful implementation of HTS relies heavily on the availability of skilled personnel. The shortage of trained professionals in this field can lead to non-compliance and improper screening of drug targets. Consequently, product failures and regulatory issues can result in significant financial losses for companies. This issue is particularly prevalent in developing countries, where the healthcare system lacks the necessary workforce to effectively utilize HTS technology. To mitigate this challenge, it is essential for organizations to invest in training and development programs for their staff, ensuring they have the necessary expertise to operate HTS equipment effectively and efficiently.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview 

This high throughput screening (HTS) market report extensively covers market segmentation by  

Application 1.1 Target identification and validation1.2 Primary and secondary screening1.3 Toxicology assessment1.4 Stem cell researchEnd-user 2.1 Pharmaceutical and biotechnology companies2.2 Academic and research institutes2.3 CROsGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Target identification and validation-  The global high throughput screening (HTS) market is driven by the increasing need for target identification and validation in drug development. This process involves finding potential therapeutic targets for diseases or conditions without existing treatments or inadequate current options. Early and thorough target identification and validation establish a strong link to clinical trial success. Chronic diseases like cardiovascular diseases, cancer, and respiratory diseases, which have a high global prevalence, fuel the demand for new targets. Additionally, the growing pipeline for biological candidates, outsourcing from pharmaceutical companies, and regulatory agencies’ demand for accurate drug and process development details contribute to market expansion. Advanced bioinformatics tools, automated experimental designs, and AI/ML algorithms are enhancing target identification and validation, further boosting the segment’s growth. Consequently, these factors are expected to fuel the growth of the target identification and validation segment in the global high throughput screening market during the forecast period.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

High-throughput screening (HTS) is a critical technology in the global healthcare sector, enabling the rapid and efficient identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, often containing hundreds of thousands to millions of compounds, which are screened against disease targets using automated systems. These systems include robotic arms, microplate readers, and high-resolution imaging systems. Data analytics plays a crucial role in HTS, with data management systems, data storage, data organization, data retrieval, data integration, and chemical databases essential for processing and interpreting the vast amounts of data generated. Academic institutions, biotech startups, research organizations, and pharmaceutical corporations all contribute to the HTS market, with open innovation models facilitating collaboration and knowledge sharing. Drug repurposing, the process of discovering new uses for existing drugs, is also a significant application of HTS. The market for HTS is expected to grow significantly due to the increasing demand for new and effective treatments for various diseases.

Market Research Overview

High Throughput Screening (HTS) is a critical technology in the life sciences sector, enabling the rapid identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, automation, and specialized equipment like robotic arms, microplate readers, and high-resolution imaging systems to screen large numbers of compounds against specific targets. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to organize, store, retrieve, integrate, and analyze genomic data and chemical databases. Collaborative networks and HTS service providers facilitate open innovation models and knowledge sharing among academic institutions, biotech startups, pharmaceutical corporations, and research organizations. Drug repurposing initiatives and biopharmaceutical industry leaders are leveraging HTS for precision medicine and target identification, while toxicology and stem cell research also benefit from this technology. The global healthcare sector continues to invest in HTS for drug discovery, clinical trials, and product development, driving the market for instruments, software, and consumables.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ApplicationTarget Identification And ValidationPrimary And Secondary ScreeningToxicology AssessmentStem Cell ResearchEnd-userPharmaceutical And Biotechnology CompaniesAcademic And Research InstitutesCROsGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/high-throughput-screening-hts-market-to-grow-by-usd-19-9-billion-2024-2028-boosted-by-rising-rd-investments-with-ai-redefining-market-landscape—technavio-302364447.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Trident Systems Recognized by Northrop Grumman with Supplier Excellence Award

Published

on

By

FAIRFAX, Va., March 4, 2025 /PRNewswire/ — Northrop Grumman Corporation (NYSE:NOC) has recognized Trident Systems, a LightRidge Solutions Company, as one of its top supplier partners during the company’s Supplier Excellence Awards.

“Trident has supported Northrop Grumman in delivering technologies that enhance national security for the U.S. and our allies,” said Ken Brown, vice president, enterprise global supply chain, Northrop Grumman. “The high-quality performance, dedication and partnership of our supplier teams drive operational excellence to ensure warfighters have next generation advantages in advanced weapons, aircraft, missile defense and space.”

Recognized for Strategic Excellence, Trident is instrumental in supporting Northrop Grumman by delivering innovative and cost-effective military and security solutions to give its customers the advantage in a complex world.

“We are honored to be recognized by Northrop Grumman as a partner delivering strategic excellence,” said Daniel Hibbard, president of space electronic systems at Trident Systems. “Our partners turn to us to provide purpose-built solutions for their most challenging missions. We pride ourselves on the flexibility and interoperability of our open architecture systems allowing ease and speed of integration with third-party parts, keeping cost down for our customers while delivering proven and reliable flight units on schedule.”

Learn more about Trident’s leading-edge space solutions.

About Trident Systems
Trident Systems has cemented its reputation for over three decades as a leader in multi-function space electronics and integrated C4ISR solutions. Using a rapid response, radiation effects-mitigated design approach for deployment in harsh environments, Trident has delivered semi-custom, high-performance mission computing solutions at significantly lower cost than traditional space processors. The company is also relied upon by a range of military and federal organizations dedicated to the design, development and deployment of innovative command and control systems for the safety and survivability of our armed forces and for the protection of the National Capital Region. For more information, please visit https://tridsys.com/.

About LightRidge Solutions
LightRidge Solutions brings leading capabilities that address demanding national security space and defense needs. Our capabilities include advanced space payloads and on-orbit processing technologies, multi-orbit space domain awareness and protection systems, laser communications and airborne survivability systems, as well as mission autonomy software. LightRidge’s innovative and highly reliable purpose-built systems provide high performance at lower costs and on shorter delivery schedules than traditional systems. These systems enable the transition to more resilient and affordable space architectures for the U.S. military and intelligence communities, as well as select commercial and international customers. For more information, please visit https://www.lightridgesolutions.com/ and visit us on LinkedIn.

Contact: Diane Hockenberry       
703-244-0226

View original content to download multimedia:https://www.prnewswire.com/news-releases/trident-systems-recognized-by-northrop-grumman-with-supplier-excellence-award-302392107.html

SOURCE LightRidge Solutions Holding LLC

Continue Reading

Technology

Canada launches first-ever Artificial Intelligence Strategy for the federal public service

Published

on

By

WATERLOO, ON, March 4, 2025 /CNW/ – Artificial intelligence (AI) has the potential to significantly improve government operations and services for Canadians. The safe, ethical and responsible use of AI is a priority for the federal government.

Today, the Honourable Ginette Petitpas Taylor, President of the Treasury Board, launched Canada’s first AI Strategy for the federal public service at the University of Waterloo, a hub for emerging technology and Canadian talent. Announcing the Strategy at the Waterloo Data and Artificial Intelligence Institute underscores the government’s commitment to research and innovation in AI to improve digital service delivery.

The Strategy was developed through extensive engagement with stakeholders, including the public and experts from a range of disciplines. Involving Canadians in its development was a key feature to ensure it reflected the democratic values we continue to prioritize today.

Accordingly, the Strategy will advance 4 key priority areas: establishing an AI Centre of Expertise to support and to help coordinate government-wide AI efforts; ensuring AI systems are secure and used responsibly; providing training and talent development pathways; and building trust through openness and transparency in how AI is used.

The Government of Canada will use AI to enhance its scientific and research capabilities, improve the productivity of its workforce, and deliver enhanced digital services to Canadians. This work will strengthen Canada’s role as a leader in AI.

Through this Strategy, the government will be able to implement AI more efficiently by removing barriers to AI adoption that exist in departmental processes and legacy systems. It will promote more effective collaboration between government departments to identify successful AI-driven initiatives and implement them more widely. As well, the Strategy strengthens transparency and accountability for the responsible use of AI, ensuring the development of AI solutions that are ethical, inclusive, and responsive to the needs of the public.

Quote

“Today’s announcement positions Canada as a global leader in the responsible use of AI in the public service. With the first-ever AI Strategy for the public service, we’re laying the groundwork to leverage the potential of this technology to deliver the best possible services to Canadians.”

–       The Honourable Ginette Petitpas Taylor, President of the Treasury Board

Quick Facts

The AI Strategy supports Canada’s Digital Ambition, which outlines how the government will provide Canadians with modern services that are secure, reliable, user-centric and barrier-free. 

From May to October 2024, as part of the development of the Strategy, the Government of Canada sought input from various groups through engagement and consultation, and in January 2025 published a “What We Heard” report summarizing the views shared by Canadians.

Every 2 years, the government will aim to update the Strategy to ensure it remains relevant and responsive.

Guide on the use of Generative AI is available for public servants to assess the risks associated with generative AI and use it responsibly.

Associated Links

AI Strategy for the Federal Public ServiceStatement from the President of the Treasury Board on advancing digital government – Canada.caMinister Anand launches public consultations on Canada’s first artificial intelligence strategy for the federal public service – Canada.caMinister Anand hosts AI roundtable to inform the first-ever artificial intelligence strategy for the federal public service – Canada.caResponsible use of artificial intelligence in government – Canada.ca

Stay connected
X: @TBS_Canada
Facebook: https://www.facebook.com/TBSCanada
LinkedIn: https://www.linkedin.com/company/tbs-sct/

SOURCE Treasury Board of Canada Secretariat

Continue Reading

Technology

Dr. Randi Boyette Joins American Med Spa Association as Corporate Development Advisor

Published

on

By

The American Med Spa Association (AmSpa) proudly welcomes Randi Boyette, PhD, as its new Corporate Development Advisor. With an extensive background in medical aesthetics, business strategy, marketing, and technology, Dr. Boyette will play a pivotal role in expanding AmSpa’s reach, fostering strategic partnerships, and enhancing the resources available to medical spa professionals nationwide.

CHICAGO, March 4, 2025 /PRNewswire-PRWeb/ — Dr. Boyette has spent her career at the intersection of medical aesthetics, corporate growth, and business development. She has worked with thousands of medical spas and clinics, helping them scale, refine operations, and optimize profitability. Her expertise in guiding businesses through market changes, implementing high-impact growth strategies, and aligning organizations with emerging trends makes her a valuable addition to the AmSpa leadership team.

“AmSpa has been instrumental in shaping the medical aesthetics industry by providing critical education, legal guidance, and business strategies,” said Dr. Boyette.

“AmSpa has been instrumental in shaping the medical aesthetics industry by providing critical education, legal guidance, and business strategies,” said Dr. Boyette. “I am honored to join this team and look forward to helping AmSpa members strengthen their businesses and navigate the evolving aesthetics landscape.”

As the industry continues to evolve, AmSpa remains committed to delivering innovative resources and opportunities that empower medical spa professionals to grow their businesses while staying compliant with industry regulations. Dr. Boyette’s appointment further strengthens AmSpa’s ability to support members with expert-driven insights and high-level strategic development.

Alex Thiersch, JD, Founder and CEO of AmSpa, shared his enthusiasm: “Randi has played a major role in shaping the aesthetics industry, not just through marketing but by directly helping practices scale and succeed. Her experience, connections, and hands-on approach will be a tremendous asset to our members.”

About the American Med Spa Association (AmSpa)
The American Med Spa Association (AmSpa) provides business, legal and clinical training and resources to medical spas and aesthetic practices throughout the country. AmSpa’s events—including Medical Spa Boot Camps, Academy for Injection Anatomy trainings and Medical Spa Show—provide business and legal best-practices to anyone entering the medical spa space or looking to improve their existing practice. AmSpa Members receive access to legal summaries of laws governing medical spas in their state, discounts, a robust and growing webinar library, and many other benefits. For more information visit http://www.americanmedspa.org, call 312-981-0993, or email info@americanmedspa.org.

Media Contact

Karen Spinelli, AmSpa, 872-246-0300, karen@americanmedspa.org, www.americanmedspa.org

Twitter Facebook

View original content:https://www.prweb.com/releases/dr-randi-boyette-joins-american-med-spa-association-as-corporate-development-advisor-302391852.html

SOURCE AmSpa

Continue Reading

Trending